The immunology market was valued at $110.1 billion in 2023 and is projected to reach $204.0 billion by 2033, growing at a CAGR of 6.3% from 2024 to 2033.
Immunology is a branch of science involved in studying the immune system of an organism. Immune system is the defense mechanism of a living body which fights against infections, foreign substances, and diseases. Immunology finds applications in diverse disciplines of medicine, including oncology, organ transplantation, rheumatology, bacteriology, virology, parasitology, dermatology, and psychiatry.
The immunology market is driven by rise in prevalence of immunological diseases and surge in awareness among individuals regarding the treatment of such diseases. In addition, governments across the globe have increased their expenditure in the field of science and medicine, thereby augmenting the growth of the immunology market. Boost in the trend of biosimilars and personalized medicine is currently presenting new prospects for the market. Moreover, personalized immunotherapy is projected to become mainstream in the future as a patient’s immune profile guides the treatment in this approach, hence elevating the effectiveness of the therapy and medications.
However, drug discovery is a lengthy process in immunology, which often requires 10-15 years of research in the laboratory, hence hampering the market growth. In addition, the stringent compliance requirements and the extended approval procedure of new drugs & treatments is a significant restraint for the market. For instance, the U.S. Food and Drug Administration has implemented a long series of regulations which is necessary to follow before releasing any drug in the market. This series involves preclinical testing, submission of investigational new drug application, three phases of clinical trials, submission of new drug application, and lastly post-market surveillance. Drug manufacturers are obliged to follow the sequence to ensure the efficacy and long-term effects of their medications.
Segment Review
The immunology market is segmented into product type, application, end user, and region. On the basis of product type, the market is divided into diagnostic testing equipment, biomarkers, and biopharmaceuticals. By application, it is classified into allergy & hypersensitivity, autoimmune disease, infectious disease, HIV & AIDS, and others. As per end user, it is categorized into hospitals & clinics, pharmaceutical & biotechnology companies, diagnostic laboratories, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of product type, the biopharmaceuticals segment is expected to maintain its dominance during the forecast period.
By application, the autoimmune disease segment is projected to garner a high market share by 2033.
As per end user, the hospitals & clinics segment is anticipated to be the highest shareholder during the forecast period.
Region wise, North America is predicted to maintain its dominance by 2033.
Competition Analysis
The major players operating in the global immunology market include AbbVie Inc., Johnson & Johnson, Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Amgen Inc., Eli Lilly and Company, Gilead Sciences, Inc., and Sanofi. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Immunology is a branch of science involved in studying the immune system of an organism. Immune system is the defense mechanism of a living body which fights against infections, foreign substances, and diseases. Immunology finds applications in diverse disciplines of medicine, including oncology, organ transplantation, rheumatology, bacteriology, virology, parasitology, dermatology, and psychiatry.
The immunology market is driven by rise in prevalence of immunological diseases and surge in awareness among individuals regarding the treatment of such diseases. In addition, governments across the globe have increased their expenditure in the field of science and medicine, thereby augmenting the growth of the immunology market. Boost in the trend of biosimilars and personalized medicine is currently presenting new prospects for the market. Moreover, personalized immunotherapy is projected to become mainstream in the future as a patient’s immune profile guides the treatment in this approach, hence elevating the effectiveness of the therapy and medications.
However, drug discovery is a lengthy process in immunology, which often requires 10-15 years of research in the laboratory, hence hampering the market growth. In addition, the stringent compliance requirements and the extended approval procedure of new drugs & treatments is a significant restraint for the market. For instance, the U.S. Food and Drug Administration has implemented a long series of regulations which is necessary to follow before releasing any drug in the market. This series involves preclinical testing, submission of investigational new drug application, three phases of clinical trials, submission of new drug application, and lastly post-market surveillance. Drug manufacturers are obliged to follow the sequence to ensure the efficacy and long-term effects of their medications.
Segment Review
The immunology market is segmented into product type, application, end user, and region. On the basis of product type, the market is divided into diagnostic testing equipment, biomarkers, and biopharmaceuticals. By application, it is classified into allergy & hypersensitivity, autoimmune disease, infectious disease, HIV & AIDS, and others. As per end user, it is categorized into hospitals & clinics, pharmaceutical & biotechnology companies, diagnostic laboratories, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of product type, the biopharmaceuticals segment is expected to maintain its dominance during the forecast period.
By application, the autoimmune disease segment is projected to garner a high market share by 2033.
As per end user, the hospitals & clinics segment is anticipated to be the highest shareholder during the forecast period.
Region wise, North America is predicted to maintain its dominance by 2033.
Competition Analysis
The major players operating in the global immunology market include AbbVie Inc., Johnson & Johnson, Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Amgen Inc., Eli Lilly and Company, Gilead Sciences, Inc., and Sanofi. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Product Type
- Diagnostic Testing Equipment
- Biomarkers
- Biopharmaceuticals
By Application
- Allergy and Hypersensitivity
- Autoimmune Disease
- Infectious Disease
- HIV and AIDS
- Others
By End User
- Hospitals and Clinics
- Pharmaceutical and Biotechnology Companies
- Diagnostic Laboratories
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- AbbVie Inc.
- Johnson & Johnson
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Amgen Inc.
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Sanofi
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
CHAPTER 4: IMMUNOLOGY MARKET, BY PRODUCT TYPE
CHAPTER 5: IMMUNOLOGY MARKET, BY APPLICATION
CHAPTER 6: IMMUNOLOGY MARKET, BY END USER
CHAPTER 7: IMMUNOLOGY MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
Key Market Players in the Immunology Market include:- AbbVie Inc.
- Johnson & Johnson
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Amgen Inc.
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Sanofi
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 231 |
| Published | July 2024 |
| Forecast Period | 2023 - 2033 |
| Estimated Market Value ( USD | $ 110.1 billion |
| Forecasted Market Value ( USD | $ 204 billion |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
